BIA Separations brings ‘sense of urgency’ to Zolgensma agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Krtichanut)
(Image: Getty/Krtichanut)

Related tags: SMA, BIA Separations, AveXis, Novartis, Catalent, Gene therapy, purification

AveXis and BIA Separations announce an agreement for the commercial purification process of SMA gene therapy drug Zolgensma and further gene therapy candidates.

Biochromatography development and manufacturing company, BIA Separations will work with AveXis for the commercial purification process of its newly approved gene therapy drug Zolgensma​ (onasemnogene abeparvovec-xioi) and the rest of its pipeline.

A BIA Separations spokesperson told us that it started working with AveXis, a Novartis company​, in other capacities several years ago, when it gaged the available technology for the purification of gene therapy products.

The treatment has been shown to halt disease progression in SMA patients and has become the first gene therapy for this treatment indication approved by the US Food and Drug Administration.

Zolgensma is a one-time infusion that provides a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression. If untreated SMA, a rare genetic disease, leads to progressive muscle weakness, paralysis, and can lead to permanent ventilation or death by age two.

BIA Separations will use its experience in viral and DNA purification for adeno-associated virus (AAV), and chromatographic technology for the purification and analysis of biomolecules as it supports AveXis’ gene therapy pipeline.

Andy Stober, SVP of technical operations for AveXis, stated that the work BIA has done in AAV purification and chromatographic technology were ‘important contributions’ in bringing gene therapies forward.

He added that BIA has shared and operated with “the same sense of urgency” ​as AveXis to “bring gene therapy to the SMA community.”

Catalent contributions

After the approval of Zolgensma, Catalent Biologics’ newly purchased subsidiary Paragon​ entered an agreement with AveXis as well. Per the agreement, Paragon will develop and manufacture Zolgensma in a dedicated production space at its commercial manufacturing center in Maryland, US.

Paragon will provide AveXis with access to Catalent’s AAV gene therapy development, manufacturing, and process characterization capabilities, and process development for clinical supply of any additional viral therapies in AveXis’ pipeline.

Additionally, Novartis entered an agreement with SAVSU Technologies​ to use the company’s cold chain shipment technology as AveXis’ pipeline develops.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers